Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006;11(3):190–8.

Article  CAS  PubMed  Google Scholar 

Takamochi K, Oh S, Matsunaga T, Suzuki K. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2017;154(5):1768-74.e1.

Article  CAS  PubMed  Google Scholar 

Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23(11):2513–20.

Article  CAS  PubMed  Google Scholar 

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.

Article  CAS  PubMed  Google Scholar 

Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41(10):1830–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389(2):137–47.

Article  CAS  PubMed  Google Scholar 

Watanabe Y, Hattori A, Nojiri S, Matsunaga T, Takamochi K, Oh S, Suzuki K. Clinical impact of a small component of ground-glass opacity in solid-dominant clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022;163(3):791-801.e4.

Article  PubMed  Google Scholar 

Hattori A, Suzuki K, Takamochi K, Wakabayashi M, Aokage K, Saji H, Watanabe SI. Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021;161(4):1469–80.

Article  PubMed  Google Scholar 

Suda K, Mitsudomi T, Shintani Y, Okami J, Ito H, Ohtsuka T, et al. Clinical impacts of egfr mutation status: analysis of 5780 surgically resected lung cancer cases. Ann Thorac Surg. 2021;111(1):269–76.

Article  PubMed  Google Scholar 

Yatabe Y, Borczuk AC, Powell CA. Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer. 2011;74(1):7–11.

Article  PubMed  Google Scholar 

Kobayashi Y, Mitsudomi T, Sakao Y, Yatabe Y. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. Ann Oncol. 2015;26(1):156–61.

Article  CAS  PubMed  Google Scholar 

Aokage K, Miyoshi T, Wakabayashi M, Ikeno T, Suzuki J, Tane K, et al. Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma. Lung Cancer. 2021;160:8–16.

Article  CAS  PubMed  Google Scholar 

Deng C, Zhang Y, Ma Z, Fu F, Deng L, Li Y, Chen H. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2021;162(3):664-74.e7.

Article  PubMed  Google Scholar 

Hattori A, Matsunaga T, Fukui M, Takamochi K, Suzuki K. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features. Eur J Cardiothorac Surg. 2022;61(4):769–77.

Article  PubMed  Google Scholar 

Yang F, Sun K, Li F, Li X, Shi J, Sun X, et al. The prognostic impact of epidermal growth factor receptor mutation in clinical stage I lung adenocarcinoma. Ann Thorac Surg. 2023. https://doi.org/10.1016/j.athoracsur.2023.05.031.

Article  PubMed  Google Scholar 

WHO Classification of Tumors Editorial Board. WHO classification of tumours: thoracic tumours. 5th ed. Lyon, France.: International Agency for Research on Cancer; 2021.; 2021.

Nagai Y, Miyazawa H, Huqun TT, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65(16):7276–82.

Article  CAS  PubMed  Google Scholar 

Hattori A, Hirayama S, Matsunaga T, Hayashi T, Takamochi K, Oh S, Suzuki K. Distinct clinicopathologic characteristics and prognosis based on the presence of ground glass opacity component in clinical stage IA lung adenocarcinoma. J Thorac Oncol. 2019;14(2):265–75.

Article  PubMed  Google Scholar 

Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75(12):2844–52.

Article  CAS  PubMed  Google Scholar 

Suehisa H, Toyooka S, Hotta K, Uchida A, Soh J, Fujiwara Y, et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol. 2007;25(25):3952–7.

Article  CAS  PubMed  Google Scholar 

Tsutani Y, Ito M, Shimada Y, Ito H, Ikeda N, Nakayama H, Okada M. The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. J Thorac Cardiovasc Surg. 2022;164(5):1306-15.e4.

Article  PubMed  Google Scholar 

Aoki M, Miyata R, Kamimura G, Harada Takeda A, Suetsugu T, Mizuno K, Ueda K. Effect of tegafur-uracil in resected stage IB lung adenocarcinoma according to presence or absence of epidermal growth factor receptor gene mutation: a retrospective cohort study. Ann Thorac Cardiovasc Surg. 2024. https://doi.org/10.5761/atcs.oa.23-00134.

Article  PubMed  PubMed Central  Google Scholar